<DOC>
	<DOCNO>NCT01524978</DOCNO>
	<brief_summary>This open-label , multi-center study ass efficacy safety Zelboraf ( vemurafenib ) patient BRAF V600 mutation-positive cancer ( solid tumor multiple myeloma , except melanoma papillary thyroid cancer ) Zelboraf deem best treatment option opinion investigator . Patients receive twice daily oral dos 960 mg Zelboraf disease progression , unacceptable toxicity , withdrawal consent . The safety efficacy Zelboraf combination cetuximab subset patient colorectal cancer also assess .</brief_summary>
	<brief_title>A Study Zelboraf ( Vemurafenib ) Patients With BRAF V600 Mutation-Positive Cancers</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Must recover side effect recent systemic local treatment Adequate hematological , renal liver function For solid tumor : Histologically confirm cancer ( exclude melanoma papillary thyroid cancer ) BRAF V600 mutation resistant standard therapy standard curative therapy exist Measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) For multiple myeloma : Confirmed diagnosis multiple myeloma BRAF V600 mutation Patients must receive least one prior systemic therapy treatment multiple myeloma Patients treat local radiotherapy Patients must relapse and/or refractory multiple myeloma measurable disease Melanoma , papillary thyroid cancer hematological malignancy ( exception multiple myeloma ) Uncontrolled concurrent malignancy For patient multiple myeloma : solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia Active untreated CNS metastasis History know carcinomatous meningitis Concurrent administration anticancer therapy administer study Other severe , acute , chronic medical psychiatric condition laboratory abnormality would , investigator 's opinion , contraindicate participation study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>